• Japanese
  • Korean
  • Chinese
Cover Image

Gynecology Partnering Terms and Agreements

The ‘Gynecology Partnering Terms and Agreements’ report provides comprehensive understanding and unprecedented access to the gynecology partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter gynecology partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors gynecology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 500 links to online copies of actual gynecology deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of gynecology dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in gynecology dealmaking since 2009 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading gynecology deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of gynecology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all gynecology deals since 2009 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all gynecology partnering deals signed and announced since 2009. The chapter is organized by specific gynecology therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all gynecology partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in gynecology partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of gynecology technologies and products.

Benefits

‘Gynecology Partnering Terms and Agreements’ provides the reader with the following key benefits:

  • In-depth understanding of gynecology deal trends since 2009
  • Access gynecology deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between gynecology partner companies
  • Comprehensive access to over 500 links to actual gynecology deals entered into by the world's biopharma companies
  • Indepth review of gynecology deals entered into by the leading fifty bigpharma companies
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner gynecology opportunities
  • Uncover companies actively partnering gynecology opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in gynaecology dealmaking

  • 2.1. Introduction
  • 2.2. Gynaecology partnering over the years
  • 2.3. Bigpharma gynaecology dealmaking activity
  • 2.4. Bigpharma not active in gynaecology
  • 2.5. Gynaecology partnering by deal type
  • 2.6. Gynaecology partnering by industry sector
  • 2.7. Gynaecology partnering by stage of development
  • 2.8. Gynaecology partnering by technology type
  • 2.9. Gynaecology partnering by gyneacology indication
  • 2.10. Average deal terms for gynaecology
    • 2.10.1. Gynaecology headline values
    • 2.10.2. Gynaecology upfront payments
    • 2.10.3. Gynaecology milestone payments
    • 2.10.4. Gynaecology royalty rates

Chapter 3 - Leading gynaecology deals

  • 3.1. Introduction
  • 3.2. Top gynaecology deals by value
  • 3.3. Top gynaecology deals involving bigpharma

Chapter 4 - Bigpharma gynaecology deals

  • 4.1. Introduction
  • 4.2. How to use bigpharma partnering deals
  • 4.3. Bigpharma gynaecology partnering company profiles
    • Abbott
    • Amgen
    • AstraZeneca
    • Bayer
    • GlaxoSmithKline
    • Johnson & Johnson
    • Merck & Co
    • Merck KGaA
    • Mylan
    • Novartis
    • Pfizer
    • Roche
    • Shionogi
    • Shire
    • Teva
    • Warner Chilcott
    • Watson

Chapter 5 - Gynaecology partnering contracts directory

  • 5.1. Introduction
  • 5.2. By deal type
    • Asset purchase
    • Co-development
    • Collaborative R&D
    • Contract service
    • Development
    • Distribution
    • Equity purchase
    • Evaluation
    • Licensing
    • Litigation
    • Manufacturing
    • Marketing
    • Option
    • Research
    • Settlement
    • Sub-license
    • Supply
    • Termination
  • 5.3. By stage of development
    • Discovery
    • Formulation
    • Marketed
    • Phase I
    • Phase II
    • Phase III
    • Preclinical
    • Regulatory
  • 5.4. By technology type
    • Biological compounds
    • Biomarkers
    • Diagnostic - companion
    • Devices
    • Diagnostics
    • Drug delivery
    • Enabling technology
    • Equipment
    • Genomics
    • Natural product
    • Peptides
    • Recombinant DNA
    • Screening
    • Small molecules
    • Vaccines

Chapter 6 - Gynaecology dealmaking by indication

  • 6.1. Introduction
  • 6.2. Deals by therapeutic indication
    • Gynaecology
    • Cervical Intraepithelial Neoplasia
    • Endometriosis
    • Fibroids
    • Amenorrhea
    • Dysmenorrhea
    • Pelvic
    • Human papillomavirus
    • Infertility
    • Menopause
    • Pelvic inflammatory disease
    • Vaginitis

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Directory of gynaecology deals by company A-Z 2009-2014
  • Appendix 2 - Directory of gynaecology deals by deal type 2009-2014
  • Appendix 3 - Directory of gynaecology deals by stage of development 2009-2014
  • Appendix 4 - Directory of gynaecology deals by technology type 2009-2014
  • Appendix 5 - Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent titles from CurrentPartnering
  • Order Form - Reports
  • Order Form - Therapy Reports

Table of Figures

  • Figure 1: Gynaecology partnering since 2009
  • Figure 2: Bigpharma - top 50 - gynaecology deals 2009 to 2012
  • Figure 3: Bigpharma gynaecology deal frequency - 2009 to 2012
  • Figure 4: Inactive bigpharma in gynaecology 2009-2014
  • Figure 5: Gynaecology partnering by deal type since 2009
  • Figure 6: Gynaecology partnering by industry sector since 2009
  • Figure 7: Gynaecology partnering by stage of development since 2009
  • Figure 8: Gynaecology partnering by technology type since 2009
  • Figure 9: Gynaecology partnering by gynaecology target since 2009
  • Figure 10: Gynaecology deals with a headline value
  • Figure 11: Gynaecology deal headline value distribution, US$million - discovery stage
  • Figure 12: Gynaecology deal headline value distribution, US$million - preclinical stage
  • Figure 13: Gynaecology deal headline value distribution, US$million - phase I stage
  • Figure 14: Gynaecology deal headline value distribution, US$million - phase II stage
  • Figure 15: Gynaecology deal headline value distribution, US$million - phase III stage
  • Figure 16: Gynaecology deal headline value distribution, US$million - regulatory stage
  • Figure 17: Gynaecology deal headline value distribution, US$million - marketed stage
  • Figure 18: Summary median headline value by stage of development, 2009-2014
  • Figure 19 Gynaecology deals with upfront payment values
  • Figure 20: Gynaecology deal upfront payment distribution, US$million - discovery stage
  • Figure 21: Gynaecology deal upfront payment distribution, US$million - preclinical stage
  • Figure 22: Gynaecology deal upfront payment distribution, US$million - phase I stage
  • Figure 23: Gynaecology deal upfront payment distribution, US$million - phase II stage
  • Figure 24: Gynaecology deal upfront payment distribution, US$million - phase III stage
  • Figure 25: Gynaecology deal upfront payment distribution, US$million - regulatory stage
  • Figure 26: Gynaecology deal upfront payment distribution, US$million - marketed stage
  • Figure 27: Summary median upfront payments by stage of development, 2009-2014
  • Figure 28: Gynaecology deals with milestone payments
  • Figure 29: Gynaecology deal milestone distribution, US$million - discovery stage
  • Figure 30: Gynaecology deal milestone distribution, US$million - preclinical stage
  • Figure 31: Gynaecology deal milestone distribution, US$million - phase I stage
  • Figure 32: Gynaecology deal milestone distribution, US$million - phase II stage
  • Figure 33: Gynaecology deal milestone distribution, US$million - phase III stage
  • Figure 34: Gynaecology deal milestone distribution, US$million - regulatory stage
  • Figure 35: Gynaecology deal milestone distribution, US$million - marketed stage
  • Figure 36: Gynaecology deals with royalty rates, %
  • Figure 37: Gynaecology deal royalty rate distribution, US$million - discovery stage
  • Figure 38: Gynaecology deal royalty rate distribution, US$million - preclinical stage
  • Figure 39: Gynaecology deal royalty rate distribution, US$million - phase I stage
  • Figure 40: Gynaecology deal royalty rate distribution, US$million - phase II stage
  • Figure 41: Gynaecology deal royalty rate distribution, US$million - phase III stage
  • Figure 42: Gynaecology deal royalty rate distribution, US$million - regulatory stage
  • Figure 44: Summary median royalty rate by stage of development, 2009-2014
  • Figure 45: Top gynaecology deals by value since 2009
  • Figure 46: Top gynaecology deals signed by bigpharma value since 2009
  • Figure 47: Online partnering resources
  • Figure 48: Forthcoming partnering events
Show More
Pricing
Get Notified
Email me when related reports are published